Applied BioCode Corp is engaged in the provision of digital biological barcode detection technology platforms and related products. The Company's products mainly include digital biological barcodes, optical analyzers, in vitro diagnostic reagents, and others. The Company sells products in the United States, Europe and Asian markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-28	NT$29.10	0.00%	254,450
26-10-28	NT$29.10	-1.69%	205,213
26-10-27	NT$29.60	-2.31%	226,094
26-10-22	NT$30.30	0.00%	397,940
26-10-21	NT$30.30	+5.03%	622,233

End-of-day quote Taiwan S.E.

More quotes

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Applied BioCode Corporation

Company calendar

End-of-day quote Taiwan S.E. 2026-10-29			5-day change	1st Jan Change
29.10 ^TWD	0.00%		-3.96%	+32.27%

10-12	VITALiS Health, Inc. Selects Applied BioCode, Inc. As Preferred Solution Provider For Molecular Gastrointestinal Pathogen Panel Testing	CI
09-08	Henry Schein to Distribute Applied BioCode's MDx-3000 System in US	MT

Market Cap	2.99B 92.2M 82.73M 76.48M 69.27M 129M 8.78B 131M 914M 364M 4.6B 346M 339M 14.59B	P/E 2024	-7x	P/E 2025	-11.2x
Enterprise Value	2.48B 76.49M 68.62M 63.45M 57.46M 107M 7.28B 109M 759M 302M 3.81B 287M 281M 12.1B	EV / Sales 2024	3.59x	EV / Sales 2025	3.69x
Free-Float	66.78%	Yield 2024 *	-	Yield 2025	-

10-12	VITALiS Health, Inc. Selects Applied BioCode, Inc. As Preferred Solution Provider For Molecular Gastrointestinal Pathogen Panel Testing	CI
09-08	Henry Schein to Distribute Applied BioCode's MDx-3000 System in US	MT
08-24	Applied BioCode Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-14	Applied BioCode Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-04	Applied BioCode Announces FDA Clearance for KingFisher? Nucleic Acid Extraction with BioCode® Respiratory Pathogen Panel for IVD Use	CI
05-04	Applied BioCode Unit Gets US FDA Nod for Respiratory Pathogen Panel	MT
03-12	Applied BioCode Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-22	Applied BioCode Submits BioCode Respiratory Pathogen Panel with Kingfisher Nucleic Acid Extraction Claim to the FDA	CI
11-11	Applied BioCode Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-26	Applied BioCode Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-12	Applied Biocode Corporation Announces Appointment of Remuneration Committee Members, Effective June 12, 2025	CI
25-06-06	Applied Biocode Corporation Announces Audit Committee Changes	CI
25-06-06	Applied Biocode Corporation Announces Remuneration Committee Changes	CI

08-11	Applied BioCode Reports Record Financial Results for the First Half of 2026; Revenue Increases 81% Year Over Year, Driven by Strong U.S. Molecular Diagnostics Growth	AQ
25-01-14	Applied BioCode Announces New Nucleic Acid Extraction Claim for KingFisher™ Flex Nucleic Acid Purification System with BioCode® Gastrointestinal Pathogen Panel (GPP)	BU
24-04-15	Applied BioCode Announces the Launch of the STI + Resistance Panel Assay for Research Use Only	BU
24-03-21	Applied BioCode Announces Retirement of CEO Chris Bernard	BU
23-09-28	Applied BioCode Appoints Industry Veteran Beth Laderman as Chief Scientific Officer	BU

Applied BioCode Corporation Stock

Stocks

6598

KYG0488D1051

Biotechnology & Medical Research

Valuation: Applied BioCode Corporation

Chart: Applied BioCode Corporation

Latest news: Applied BioCode Corporation

Press Releases: Applied BioCode Corporation

Quotes and Performance

Price Extremes

Managers and Directors: Applied BioCode Corporation

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

1 week	-3.96%
Current month	+6.20%
1 month	+6.59%
6 months	+32.88%
Current year	+32.27%

1 week	28.4	30.55
1 month	26	31.2
Current year	21.45	31.9
1 year	20.5	31.9
3 years	17	33.6
5 years	17	60.7
10 years	17	182.5

Manager	Title	Age	Since
Zonh Zen Ho CEO	Chief Executive Officer	-	2007-12-31
Liang Kai Huang DFI	Director of Finance/CFO	-	2018-01-31
Joseph Ingrid ADM	Chief Administrative Officer	-	2020-07-31

Director	Title	Age	Since
George Lee CHM	Chairman	75	2016-06-29
Benjamin Jen BRD	Director/Board Member	60	2016-09-28
Ta Cheng Hsu BRD	Director/Board Member	-	2025-06-05

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APPLIED BIOCODE CORPORATION	0.00%	-3.96%	+26.25%	+35.98%	92.2M
WUXI APPTEC CO., LTD.	+0.34%	-3.03%	+37.45%	+61.06%	64.14B
ARGENX SE	+0.83%	+2.60%	+12.17%	+83.77%	55.53B
LONZA GROUP AG	+1.06%	+1.40%	+12.62%	+104.49%	53.03B
IQVIA HOLDINGS INC.	-1.27%	-1.11%	+26.36%	+55.36%	45.99B
BEONE MEDICINES AG	-0.07%	-2.04%	+18.94%	+100.67%	42.45B
REVOLUTION MEDICINES, INC.	+0.36%	+1.75%	+229.16%	+940.76%	40.45B
CELLTRION, INC.	+0.64%	-3.95%	+11.15%	+45.57%	32.25B
GENMAB A/S	-2.15%	+43.59%	+105.00%	+91.41%	34.47B
WUXI BIOLOGICS (CAYMAN) INC.	-2.72%	-0.44%	+23.18%	-10.77%	24.23B
Average	-0.22%	+3.07%	+50.23%	+150.83%	39.26B
Weighted average by Cap.	-0.03%	+3.15%	+49.86%	+161.33%

	2024	2025
Net sales	343M 10.57M 9.49M 8.77M 7.94M 14.84M 1.01B 15.02M 105M 41.76M 527M 39.67M 38.84M 1.67B	475M 14.64M 13.14M 12.15M 11M 20.55M 1.39B 20.8M 145M 57.85M 730M 54.95M 53.79M 2.32B
Net income	-261M -8.04M -7.21M -6.67M -6.04M -11.28M -765M -11.42M -79.71M -31.75M -401M -30.16M -29.52M -1.27B	-201M -6.2M -5.56M -5.14M -4.66M -8.7M -591M -8.81M -61.49M -24.49M -309M -23.27M -22.78M -981M
Net Debt	-838M -25.82M -23.17M -21.42M -19.4M -36.24M -2.46B -36.68M -256M -102M -1.29B -96.9M -94.86M -4.09B	-510M -15.72M -14.1M -13.04M -11.81M -22.06M -1.5B -22.33M -156M -62.09M -783M -58.98M -57.74M -2.49B